News

EuropaWire11m
Novartis Announces Positive Interim Results for Pluvicto™ in Early-Stage Prostate Cancer, Meeting Primary Endpoint in Phase III PSMAddition Trial
Novartis has announced that its Phase III PSMAddition trial of Pluvicto™ in combination with standard of care (SoC) has met its primary endpoin ...
EuropaWire49m
Novartis Presents ASCO Data Showing Kisqali’s Efficacy and Tolerability in High-Risk Early Breast Cancer Patients
Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in ...